

1.1 moves to amend H.F. No. 81 as follows:

1.2 Delete everything after the enacting clause and insert:

1.3 "Section 1. **PHARMACOGENOMICS TASK FORCE.**

1.4 Subdivision 1. Establishment and purpose. (a) The legislature finds that it is important
1.5 to examine the promising new health innovation of pharmacogenomics and its potential to
1.6 improve medication efficacy and safety, and ultimately achieve better health outcomes for
1.7 Minnesotans. The Board of Pharmacy shall establish a pharmacogenomics task force to:

1.8 (1) evaluate and assess the current availability of clinical pharmacogenomics in
1.9 Minnesota;

1.10 (2) conduct a comprehensive analysis of strategies that could be undertaken to implement
1.11 pharmacogenomics across the state;

1.12 (3) evaluate aspects of payer reimbursement for pharmacogenomics testing;

1.13 (4) assess the potential to advance health equity and improve medication use through
1.14 pharmacogenomics in diverse and medically underserved populations in Minnesota, such
1.15 as Hmong, Native American, and Somali communities;

1.16 (5) determine ethical, legal, and social implications of pharmacogenomics;

1.17 (6) determine requirements to protect data and privacy as it relates to pharmacogenomics;

1.18 (7) determine the education needed for successful clinical pharmacogenomics
1.19 implementation; and

1.20 (8) develop recommendations for making pharmacogenomics available statewide.

1.21 (b) For purposes of this section, "pharmacogenomics" means the determination of how
1.22 variation in an individual's genomic information influences medication safety and efficacy.

2.1 The provisions of Minnesota Statutes, section 15.059, subdivision 6, shall govern the terms,
2.2 compensation, and removal of members of the task force, except that the members may
2.3 receive a per diem as specified in Minnesota Statutes, section 15.059, subdivision 3.

2.4 Subd. 2. **Membership.** (a) The pharmacogenomics task force shall consist of members
2.5 appointed by the executive director of the Board of Pharmacy according to paragraph (c)
2.6 and four members of the legislature appointed according to paragraph (e).

2.7 (b) The task force will elect a chair and co-chair and other officers as the members deem
2.8 necessary.

2.9 (c) The executive director shall appoint the following members:

2.10 (1) at least two pharmacists with expertise in pharmacogenomics from the University
2.11 of Minnesota;

2.12 (2) at least two other pharmacists licensed and practicing within the state with expertise
2.13 in pharmacogenomics;

2.14 (3) at least two physicians licensed and practicing in the state;

2.15 (4) at least two health system or clinic administrators, or their designees, from the state;

2.16 (5) a representative of a patient organization that operates in the state;

2.17 (6) a patient or caregiver with an interest in pharmacogenomics;

2.18 (7) a pharmacist or other provider who is a member of a diverse and underrepresented
2.19 community;

2.20 (8) a second member of a diverse and underrepresented community;

2.21 (9) a representative of the biotechnology industry;

2.22 (10) a representative of payers, health plans, or insurers;

2.23 (11) an expert in health informatics from the University of Minnesota;

2.24 (12) an expert in data management and security;

2.25 (13) an expert in ethical, legal, and social implications of genomics;

2.26 (14) an expert in health regulatory affairs from the state; and

2.27 (15) a genetic counselor.

2.28 (d) Members appointed according to paragraph (c) shall reflect an equitable statewide
2.29 geographical representation and representation from diverse groups within the state.

3.1 (e) The pharmacogenomics task force shall include two members of the senate, one
3.2 appointed by the majority leader and one appointed by the minority leader, and two members
3.3 of the house of representatives, one appointed by the speaker of the house and one appointed
3.4 by the minority leader.

3.5 (f) The executive director or a designee shall serve as an ex officio, nonvoting member
3.6 of the pharmacogenomics task force.

3.7 (g) Initial appointments to the pharmacogenomics task force shall be made no later than
3.8 September 1, 2021. Members appointed according to paragraph (c) shall serve for a term
3.9 of one year.

3.10 Subd. 3. **Meetings.** The first meeting of the pharmacogenomics task force shall be
3.11 convened no later than October 1, 2021. The pharmacogenomics task force shall meet at
3.12 the call of the chairperson or at the request of a majority of pharmacogenomics task force
3.13 members.

3.14 Subd. 4. **Duties.** The pharmacogenomics task force's duties may include but are not
3.15 limited to:

3.16 (1) determining what education in pharmacogenomics is needed by the health care
3.17 workforce;

3.18 (2) soliciting input from the public on readiness for adoption of pharmacogenomics;

3.19 (3) soliciting input from diverse and underrepresented communities; and

3.20 (4) developing recommendations for:

3.21 (i) ensuring equitable access to and diffusion of pharmacogenomics services into practice
3.22 across the state including diverse and underrepresented communities;

3.23 (ii) necessary education for providers; and

3.24 (iii) building capacity for research on pharmacogenomics needs and capabilities across
3.25 the state.

3.26 Subd. 5. **Contracts.** The Board of Pharmacy may enter into a contract with the University
3.27 of Minnesota for facilitating and conducting research and surveys as may be needed for the
3.28 task force.

3.29 Subd. 6. **Conflict of interest.** Pharmacogenomics task force members are subject to
3.30 state policy on conflicts of interest.

4.1 Subd. 7. **Report required.** By June 30, 2022, the executive director shall report to the
4.2 chairs and ranking minority members of the legislative committees with jurisdiction over
4.3 health care policy on the activities of the pharmacogenomics task force. At a minimum, the
4.4 report must include:

4.5 (1) a description of the pharmacogenomics task force's goals; and

4.6 (2) a description of the independent recommendations made by the pharmacogenomics
4.7 task force.

4.8 Subd. 8. **Expiration.** The pharmacogenomics task force expires September 1, 2022.

4.9 Sec. 2. **APPROPRIATION.**

4.10 \$250,000 in fiscal year 2022 is appropriated from the general fund to the Board of
4.11 Pharmacy for the pharmacogenomics task force under section 1. This is a onetime
4.12 appropriation. This appropriation is available until expended."

4.13 Delete the title and insert:

4.14 "A bill for an act
4.15 relating to health; requesting the Board of Pharmacy to establish pharmacogenomics
4.16 task force; requiring a report; appropriating money."